Authors Zoellner Y, Balp M, Marco AG
Published 6 September 2011 Volume 2011:3 Pages 187—188
York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco2
1Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, Switzerland
The role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res. 2011;3:109-116.
In the results section of the abstract, "...+15% in Germany for desferrioxamine vs deferasirox." should read "...+15% in Germany for deferasirox vs desferrioxamine.
" In the ‘Compliance' section, "...and +15% in Germany for desferrioxamine vs deferasirox." should read "...and +15% in Germany for deferasirox vs desferrioxamine."
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]